The cardiovascular risk of tiotropium: Is it real?

Expert Opinion on Drug Safety

Volumn 9, Issue 5, 2010, Pages 783-792

  Cazzola, Mario ^a,c   Calzetta, Luigino ^a   Matera, Maria Gabriella ^b  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b SECOND UNIVERSITY OF NAPLES   (Italy)

^c IRCCS SAN RAFFAELE PISANA   (Italy)

Author keywords

Cardiovascular risk; COPD; Parasympathetic nervous system; Tiotropium

Indexed keywords

ATROPINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; FLUTICASONE PROPIONATE PLUS SALMETEROL; IPRATROPIUM BROMIDE; PLACEBO; TIOTROPIUM BROMIDE;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLINERGIC SYSTEM; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG SAFETY; HEART ARRHYTHMIA; HEART DISEASE; HIGH RISK PATIENT; HUMAN; META ANALYSIS; MORTALITY; NONHUMAN; RANDOMIZED CONTROLLED TRIAL; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; SYSTEMATIC REVIEW;

ADMINISTRATION, INHALATION; ANIMALS; CARDIOVASCULAR DISEASES; CASE-CONTROL STUDIES; CHOLINERGIC ANTAGONISTS; CLINICAL TRIALS AS TOPIC; COHORT STUDIES; COMORBIDITY; DISEASE SUSCEPTIBILITY; DOGS; HEART; HUMANS; META-ANALYSIS AS TOPIC; MULTICENTER STUDIES AS TOPIC; PARASYMPATHETIC NERVOUS SYSTEM; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RECEPTORS, MUSCARINIC; RISK; SCOPOLAMINE DERIVATIVES;

EID: 77955970659     PISSN: 14740338     EISSN: None     Source Type: Journal    
DOI: 10.1517/14740338.2010.500611     Document Type: Review

References (75)

1. Celli BR, MacNee W, Agusti A, et al. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 2004;23:932-946
2. Rabe KF, Hurd S, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. GOLD executive summary. Am J Respir Crit Care Med 2007;176:532-555
3. Calverley PMA, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007;356:775-789
4. Tashkin DP, Celli B, Senn S, et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 2008;359:1543-1554
5. Cazzola M. From large clinical trials to management of COPD in the real world. Ther Adv Respir Dis 2009;3:39-46
6. Barnes PJ. The role of anticholinergics in chronic obstructive pulmonary disease. Am J Med 2004;117(Suppl 12A):24S-32S
7. Currie GP, Rossiter C, Miles SA, et al. Effects of tiotropium and other long acting bronchodilators in chronic obstructive pulmonary disease. Pulm Pharmacol Ther 2006;19(2):112-119
8. Chen AM, Bollmeier SG, Finnegan PM. Long-acting bronchodilator therapy for the treatment of chronic obstructive pulmonary disease. Ann Pharmacother 2008;42:1832-1842
9. Salpeter SR. Do inhaled anticholinergics increase or decrease the risk of major cardiovascular events?: a synthesis of the available evidence. Drugs 2009;69:2025-2033
10. Anthonisen NR, Connett JE, Enright PL, Manfreda J. Hospitalizations and mortality in the Lung Health Study. Am J Respir Crit Care Med 2002;166:333-339
11. Lanes S, Golisch W, Mikl J. Ipratropium and lung health study. Am J Respir Crit Care Med 2003;167:801-802
12. Lee TA, Pickard AS, Au DH, et al. Risk for death associated with medications for recently diagnosed chronic obstructive pulmonary disease. Ann Intern Med 2008;149:380-390
13. Ogale SS, Lee TA, Au DH, et al. Cardiovascular events associated with ipratropium bromide in COPD. Chest 2010;137:13-19
14. Sin DD, Tu JV. Lack of association between ipratropium bromide and mortality in elderly patients with chronic obstructive airway disease. Thorax 2000;55:194-197
15. Brodde OE, Bruck H, Leineweber K, Seyfarth T. Presence, distribution and physiological function of adrenergic and muscarinic receptor subtypes in the human heart. Basic Res Cardiol 2001;96:528-538
16. Hellgren I, Mustafa A, Riazi M, et al. Muscarinic M3 receptor subtype gene expression in the human heart. Cell Mol Life Sci 2000;57:175-180
17. Oberhauser V, Schwertfeger E, Rutz T, et al. Acetylcholine release in human heart atrium: influence of muscarinic autoreceptors, diabetes, and age. Circulation 2001;103:1638-1643
18. Wang H, Han H, Zhang L, et al. Expression of multiple subtypes of muscarinic receptors and cellular distribution in the human heart. Mol Pharmacol 2001;59:1029-1036
19. Myslivecek J, Klein M, Novakova M, Ricny J. The detection of the non-M2 muscarinic receptor subtype in the rat heart atria and ventricles. Naunyn Schmiedebergs Arch Pharmacol 2008;378:103-116
20. Dhein S, van Koppen CJ, Brodde OE. Muscarinic receptors in the mammalian heart. Pharmacol Res 2001;44:161-182
21. Olshansky B, Sabbah HN, Hauptman PJ, Colucci WS. Parasympathetic nervous system and heart failure: pathophysiology and potential implications for therapy. Circulation 2008;118:863-871
22. Li M, Zheng C, Sato T, et al. Vagal nerve stimulation markedly improves long-term survival after chronic heart failure in rats. Circulation 2004;109:120-124
23. Bymaster FP, Carter PA, Zhang L, et al. Investigations into the physiological role of muscarinic M2 and M4 muscarinic and M4 receptor subtypes using receptor knockout mice. Life Sci 2001;68:2473-2479
24. Wang H, Shi H, Lu Y, et al. Pilocarpine modulates the cellular electrical properties of mammalian hearts by activating a cardiac M3 receptor and a K+ current. Br J Pharmacol 1999;126:1725-1734
25. Wang H, Lu Y, Wang Z. Function of cardiac M3 receptors. Auton Autacoid Pharmacol 2007;2:1-11
26. Stengel PW, Yamada M, Wess J, Cohen ML. M3-receptor knockout mice: muscarinic receptor function in atria, stomach fundus, urinary bladder, and trachea. Am J Physiol Regul Integr Comp Physiol 2002;282:R1443-9
27. Shi H, Wang H, Li D, et al. Differential alterations of receptor densities of three muscarinic acetylcholine receptor subtypes and current densities of the corresponding K+ channels in canine atria with atrial fibrillation induced by experimental congestive heart failure. Cell Physiol Biochem 2004;14:31-40
28. Tuomi JM, Chidiac P, Jones DL. Evidence for enhanced M3 muscarinic receptor function and sensitivity to atrial arrhythmia in the RGS2-deficient mouse. Am J Physiol Heart Circ Physiol 2010;298:H554-61
29. Lamping KG, Wess J, Cui Y, et al. Muscarinic (M) receptors in coronary circulation: gene-targeted mice define the role of M2 and M3 receptors in response to acetylcholine. Arterioscler Thromb Vasc Biol 2004;24:1253-1258
30. Wellstein A, Pitschner HF. Complex dose-response curves of atropine in man explained by different functions of M1- and M2-cholinoceptors. Naunyn Schmiedebergs Arch Pharmacol 1988;338:19-27
31. Pitschner HF, Schlepper M, Schulte B, et al. Selective antagonists reveal different functions of M cholinoceptor subtypes in humans. Trends Pharmacol Sci 1989;(Suppl):92-96
32. LaCroix C, Freeling J, Giles A, et al. Deficiency of M2 muscarinic acetylcholine receptors increases susceptibility of ventricular function to chronic adrenergic stress. Am J Physiol Heart Circ Physiol 2008;294:H810-20
33. Bruck H, Ulrich A, Gerlach S, et al. Effects of atropine on human cardiac beta1- and/or beta2-adrenoceptor stimulation. Naunyn Schmiedebergs Arch Pharmacol 2003;367:572-577
34. Rigel D, Lipson D, Katona P. Excess tachycardia: heart rate after antimuscarinic agents in conscious dogs. Am J Physiol 1984;246(Heart Circ Physiol 15) H168-73
35. Bauer R, Paschmann S, Wick S. Effect of (8r)-3alpha-hydroxy 8-isopropyl-lalphaH, 5alphaH-tropaniumbromide-(+)-tropate (ipratropium bromide) on tracheobronchial spasm, bronchial and salivary secretions, ECG and heart rate. Arzneimittelforsch 1976;26:981-985
36. Libersa CC, Caron JF, Kacet S, et al. Comparative cardiac effects of intravenous bolus of ipratropium bromide (itrop) and atropine sulfate in 22 patients. Clin Cardiol 1988;11:454-460
37. Kikis D, Esser H, Heinrich K. Influence of ipratropium bromide on heart rate and hemodynamics in patients with sinus bradycardia. Clin Cardiol 1982;5:441-445
38. Lehrer PM, Hochron SM, Rausch L, Carr R. Effects of aerosol ipratropium bromide on cardiac vagal tone. Chest 1994;105:1701-1704
39. Ayer A, Antic V, Dulloo AG, et al. Hemodynamic consequences of chronic parasympathetic blockade with a peripheral muscarinic antagonist. Am J Physiol Heart Circ Physiol 2007;293:H1265-72
40. Dunlap ME, Bibevski S, Rosenberry TL, Ernsberger P. Mechanisms of altered vagal control in heart failure: influence of muscarinic receptors and acetylcholinesterase activity. Am J Physiol Heart Circ Physiol 2003;285:H1632-40
41. Azevedo ER, Parker JD. Parasympathetic control of cardiac sympathetic activity: normal ventricular function versus congestive heart failure. Circulation 1999;100:274-279
42. Disse B, Speck GA, Rominger KL, et al. Tiotropium: mechanistical considerations and clinical profile in obstructive lung disease. Life Sci 1999;64:457-464
43. Koumis T, Samuel S. Tiotropium bromide: a new long-acting bronchodilator for the treatment of chronic obstructive pulmonary disease. Clin Ther 2005;27:377-392
44. Covelli H, Bhattacharya S, Cassino C, et al. Absence of electrocardiographic findings and improved function with once-daily tiotropium in patients with chronic obstructive pulmonary disease. Pharmacotherapy 2005;25:1708-1718
45. Morganroth J, Golisch W, Kesten S. Eletrocardiographic monitoring in COPD patients receiving tiotropium. COPD 2004;1:181-190
46. Kesten S, Jara M, Wentworth C, Lanes S. Pooled clinical trial analysis of tiotropium safety. Chest 2006;130:1695-1703
47. Travers J, Laveneziana P, Webb KA, et al. Effect of tiotropium bromide on the cardiovascular response to exercise in COPD. Respir Med 2007;101:2017-2024
48. De Luise C, Lanes SF, Jacobsen J, et al. Cardiovascular and respiratory hospitalizations and mortality among users of tiotropium in Denmark. Eur J Epidemiol 2007;22:267-272
49. Singh S, Loke YK, Furberg CD. Inhaled anticholinergics and risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. JAMA 2008;300:1439-1450
50. Barr RG, Bourbeau J, Camargo CA, et al. Tiotropium for stable chronic obstructive pulmonary disease: a meta-analysis. Thorax 2006;61:854-862
51. Food and Drug Administration. Early Communication about an Ongoing Safety Review of Tiotropium; 2008. Available from: www.fda.gov/cder/ drug/early-comm/tiotropium.htm. [Accessed October 2008]
52. Wedzicha JA, Calverley PM, Seemungal TA, et al. The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. Am J Respir Crit Care Med 2008;177:19-26
53. Celli B, Decramer M, Kesten S, et al. Mortality in the 4-year trial of tiotropium (UPLIFT) in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2009;180:948-955
54. Grosso A, Douglas I, Hingorani AD, et al. Inhaled tiotropium bromide and risk of stroke. Br J Clin Pharmacol 2009;68:731-736
55. Oba Y, Zaza T, Thameem DM. Safety, tolerability and risk benefit analysis of tiotropium in COPD. Int J Chron Obstruct Pulmon Dis 2008;3:575-584
56. Salpeter SR. Do inhaled anticholinergics increase or decrease the risk of major cardiovascular events? A synthesis of the available evidence. Drugs 2009;69:2025-2033
57. Moher D, Cook DJ, Eastwood S, et al. Improving the quality of reports of meta-analyses of randomized controlled trials: the QUOROM statement. Lancet 1999;354:1896-1900
58. Rodrigo GJ, Castro-Rodriguez JA, Nannini LJ, et al. Tiotropium and risk for fatal and nonfatal cardiovascular events in patients with chronic obstructive pulmonary disease: systematic review with meta-analysis. Respir Med 2009;103:1421-1429
59. Celli B, Decramer M, Leimer I, et al. Cardiovascular safety of tiotropium in patients with COPD. Chest 2010;137:20-30
60. US Food and Drug Administration. Meeting of the Pulmonary-Allergy Drugs Advisory Committee. Available from: www.fda.gov/.../CommitteesMeetingMaterials/ Drugs/Pulmonary-AllergyDrugsAdvisoryCommittee/UCM194082.pdf. [Accessed 28 May 2010]
61. Salpeter SR, Ormiston TM, Salpeter EE. Cardiovascular effects ofβ-agonists in patients with asthma and COPD: a meta-analysis. Chest 2004;125:2309-2321
62. Cazzola M, Imperatore F, Salzillo A, et al. Chest 1998;114:411-415
63. Cazzola M, Matera MG, Donner CF. Inhaledβ2-adrenoceptor agonists: cardiovascular safety in patients with obstructive lung disease. Drugs 2005;65:1595-1610
64. Jara M, Lanes SF, Wentworth C III, et al. Comparative safety of long-acting inhaled bronchodilators: a cohort study using the UK THIN primary care database. Drug Saf 2007;30:1151-1160
65. Sakamaki F, Satoh T, Nagaya N, et al. Abnormality of left ventricular sympathetic nervous function assessed by 123I-metaiodobenzylguanidine imaging in patients with COPD. Chest 1999;116:1575-1581
66. Stewart AG, Marsh F, Waterhouse JC, et al. Eur Respir J 1994;7:1090-1095
67. Cazzola M, Bettoncelli G, Sessa E, et al. Prevalence of comorbidities in patients with chronic obstructive pulmonary disease. Respiration 2010; In press
68. Curkendall SM, DeLuise C, Jones JK, et al. Cardiovascular disease in patients with chronic obstructive pulmonary disease, Saskatchewan Canada cardiovascular disease in COPD patients. Ann Epidemiol 2006;16:63-70
69. Macie C, Wooldrage K, Manfreda J, Anthonisen N. Cardiovascular morbidity and the use of inhaled bronchodilators. Int J Chron Obstruct Pulmon Dis 2008;3:163-169
70. Rabe KF. Anticholinergic drugs for the treatment of COPD are safe... are they? Chest 2010;137:1-3
71. Heredia JL. Tiotropium bromide: an update. Open Respir Med J 2009;3:43-52
72. Cazzola M, Matera MG. Should long-actingβ2-agonists be considered an alternative first choice option for the treatment of stable COPD? Respir Med 1999;93:227-229
73. Vukajlovic DD, Guettler N, Miric M, Pitschner HF. Effects of atropine and pirenzepine on heart rate turbulence. Ann Noninvasive Electrocardiol 2006;11:34-37
74. Marine JE, Watanabe MA, Smith TW, Monahan KM. Effects of atropine on heat rate turbulence. Am J Cardiol 2002;89:767-769
75. Au D, Lemaitre R, Curtis J, et al. The risk of myocardial infarction associated with inhaledβ-adrenoceptor agonists. Am J Respir Crit Care Med 2000;161:827-830